Skip to main content
main-content

The independent medical news service

19-08-2019 | Oncology | News | Article

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

01-03-2019 | Oncology | News | Article

Sex disparity identified for hyperprogressive disease after immunotherapy

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

24-10-2018 | Head and neck cancer | Video

De-ESCALaTE HPV results revealed

Hisham Mehanna describes the results of the De-ESCALaTE HPV  trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).

24-10-2018 | Head and neck cancer | Video

KEYNOTE-048: Phase III study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).

05-10-2018 | Oncology | News | Article

HPV-16 vaccine may boost nivolumab efficacy in HPV-16–positive cancer

The efficacy of programmed cell death protein 1 inhibition with nivolumab may be amplified by vaccination against human papillomavirus-16 in patients with incurable HPV-16–positive cancer, phase II study data suggest.

02-06-2018 | Head and neck cancer | News | Article

Disparity by sex may exist for head and neck cancer treatment, outcomes in USA

Women with head and neck cancer may be undertreated relative to their male counterparts, suggests research presented at the ASCO Annual Meeting 2018.

Image Credits